Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
pharmaphorum6y
Supernus says ADHD drug trounces rivals, but shares slide
Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.
Stifel maintains hold on Supernus, price target at $38
Stifel analysts maintained their Hold rating on Supernus Pharmaceuticals (NASDAQ:SUPN) shares, with a steady price target of $38.00. Trading near its 52-week high with a strong 30% gain over the past ...
Business Insider18d
Supernus announces U.S. FDA approved an update for label for Qelbree
Supernus (SUPN) Pharmaceuticals announced that ... Qelbree is approved for use in patients ages 6 years and older with ADHD. Published first on TheFly – the ultimate source for real-time ...
Yahoo Finance1y
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
By gaining a clear understanding of what ADHD is, common symptoms and how it affects people’s day to day lives, individuals can work with their doctors to choose the best course of action to suit ...
Yahoo Finance18d
Supernus Pharmaceuticals, Inc. (SUPN)
Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...